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Objective: We wished to investigate whether increased IgG infusion rates are associated with metabolic and hematologic changes
in pediatric patients with antibody deficiency syndromes. Methods: We studied 7 patients (2-16 years old) with primary antibody
deficiencies who had been on regular IgG replacement treatment, 350-600 mg/kg/dose every 3 weeks with a 3% IVIG preparation,
for periods ranging from 6 months to 4 years. Initially, the IgG concentration of IVIG preparations was increased to 6, 9 and 12% in
consecutive infusions at a constant IgG infusion rate of 4 mg/kg/min. Subsequently, the infusion rates were increased to 8, 12, and
16 mg/kg/min using the IVIG 12% preparation. Results: Clinically, all patients tolerated increases in IVIG concentrations while the
infusion rate was 4 mg/kg/min. However, 3 patients presented side effects when the infusion rate was increased to 8 and 16 mg/kg/
min. Conclusion: We conclude that metabolic and hematologic sides effects occur with rapid infusion of IVIG even in patients who
tolerate the increased infusion rate clinically. The advantages of using high infusion rates have to be re-evaluated.
Uniterms:  Intravenous immunoglobulin. Immunodeficiency. Side effects. Infusion rates. Leukopenia.
INTRODUCTION
Intravenously-infused immunoglobulins (IVIG) have
been successfully used for IgG replacement treatment in
patients with primary and secondary antibody deficiencies
(AD) and in patients with certain inflammatory and
autoimmune diseases.1-4 Adverse events associated with
the administration of IVIG preparations with IgG
concentrations ranging from 3 to 6% have been reported
in only 1 to 15% of patients (usually in less than 5%).5,6
Most of the reactions described were mild and self-limited.
Vasomotor symptoms include chills, fever, flushing,
headache, nausea, rise in temperature, vomiting and
malaise. They can probably be related to anti-
complementary activity of aggregated gammaglobulin.7
Recommended infusion rates, expressed as volume of
IVIG per patient weight for 3-6% IVIG preparations, were
0.01-0.02 ml/kg/min initially, increasing up to a maximum
rate of 0.1 ml/kg/min.2 These infusion volumes correspond
to IgG infusion rates of 0.3 to 6 mg/kg/min.
Recently, more concentrated preparations with 10-
12% IgG have become available for clinical use, leading
to considerably higher IgG infusion rates. Schiff et al.
administered 12% IVIG to 16 patients with AD at
increasing IgG infusion rates, up to a maximum of 30.6
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mg/kg/min.8  Eight patients tolerated infusion rates higher
than 10 mg/kg/min without adverse reactions, but only 5
tolerated a rate higher than 20 mg/kg/min. The observed
side effects were agitation, irritability, back pain, fever,
nausea, cold, vomiting and chills in eight patients.
Laboratory analyses were not reported.
In IVIG preparations with higher concentrations of
IgG, other pharmacologic properties like osmolarity and
pH are also changed.
The aim of this study was to investigate whether
increasing IgG concentrations and infusion rates would
induce acute metabolic and hematologic changes even
when the increases were well-tolerated clinically.
METHODS
Patient population
Patient diagnoses and doses of IgG per infusion are
summarized in Table 1. All patients had been on regular
IgG replacement treatment, 300-400 mg/kg every 3 weeks
with a 3% IVIG preparation for periods ranging from 6
months to 4 years. In one patient, the dose was increased
to 600 mg/kg because of infection occurring at lower IgG
doses.
All patients had received 3% IVIG (Sandoglobulin〉,
Sandoz, Switzerland) for at least 6 months without any
adverse reactions prior to entering the study.
All patients had normal levels of urea, creatinine,
oxaloacetic and pyruvic transaminases, and normal blood
counts before entering the study.
This study was approved by the ethical committee
of the Universidade Federal de São Paulo, Escola Paulista
de Medicina, and informed consent was obtained from
the parents of all patients.
Study design
For our study, one IVIG product (Sandoglobulin®,
Sandoz, Switzerland - diluted in saline 0.9%), prepared
with acid treatment at pH 4.0, was used in all patients.
The pH and osmolarity in the final preparations changed
with increasing concentrations of IgG: 3%: pH = 6.58
and 498 mOsm/l; 6% pH = 6.61 and 690 mOsm/l; 9%:
pH = 6.64 and 882 mOsm/l; 12%: pH = 6.8 and 1074
mOsm/l.
During the first phase of the study, we maintained a
constant infusion rate of 4 mg/kg/min with the aid of an
infusion pump (Santronic〉, São Paulo, Brazil) and
increased the IVIG concentration to 6, 9 and 12%
respectively at each new infusion. When a flow rate of
4 mg/kg/min was reached at the 12% concentration without
any side effects, we performed the second phase of the
study. In this phase, the IgG concentration of 12% was
maintained and the rate of infusion was increased at each
new infusion to 8, 12 and 16 mg/kg/min, respectively. The
rate of infusion was increased only if the patients did not
present side effects in the previous infusion.
Patients were monitored clinically before, during and
at the end of each infusion.
Plasma osmolarity and venous blood gases were
measured before and immediately after the end of each
infusion throughout the study. When the infusion rate was
increased above 4 mg/kg/min, an additional blood sample
was obtained 30 minutes after completing the infusion.
Blood-cell counts were performed before and after infusion
only when the concentration of 12% IVIG was reached.
Pre-infusion samples were obtained immediately
prior to IVIG administration. After completing the IVIG
infusion, the IV line was kept open with a saline solution.
Five to 10 minutes later, post-infusion samples were
obtained after eliminating the first 3 ml of blood to avoid
contamination with saline. A second post-infusion sample
was obtained 30 minutes after  complete IVIG
Table 1
Patient population: diagnosis and dose of IVIG/kg
Patients Age (years) Immunodeficiency Dose/mg/kg Length of treatment before study (months)
1 7 XLA* 400 18
2 5 XLA 350 48
3 5 XLA 400 18
4 11 CVI* 600 36
5 16 CVI 300 48
6 4 IgG2 D* 400 6
7 3 IgG2 D 400 6
*XLA = X-linked agammaglobulinemia; CVI = common variable
immunodeficiency; IgG2 D = IgG2 deficiency
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administration, for the determination of blood gases only.
All tests were done in the same laboratory.
Statistical analysis
Results obtained before and after IVIG infusions
were compared using the paired Student’s t test. Results
obtained before, and 5 and 30 minutes after the end of the
infusion were compared using analysis of variance
(ANOVA). Comparison of results of sequential infusions
with increasing rates were performed using ANOVA for
repeated measurements. P values are only indicated when
lower than 0.05.
RESULTS
Clinically, all seven patients tolerated the first phase
of the study, which tested increasing IgG concentrations
from 6 to 12% while maintaining a constant IgG infusion
rate of 4 mg/kg/min. In the second phase, when the infusion
rates were increased, some side effects were observed: one
patient presented abdominal pain and vomiting at an
infusion rate of 8 mg/kg/min and, when the infusion rate
was increased to 16 mg/kg/min, 2 additional patients
developed side effects. One complained of abdominal pain
during infusion, and the other, after the infusion had
headache without vomiting, which persisted for several
hours while at his home, with spontaneous remission.
Therefore, lumbar puncture was not considered necessary.
Four patients tolerated an infusion rate of 16 mg/kg/min
without any complaints. No patient had significant changes
in vital signs pre- and post-infusion.
There was a trend towards higher osmolarity after
completion of the IVIG infusion at most IVIG
concentrations and infusion rates tested (Table 2). The
percentage of increase was higher with 12% IgG than with
lower IgG concentrations. However, the increase in
osmolarity was not observed at the highest infusion rate
of 16 mg/kg/min. None of the changes in osmolarity
reached significance and all values were within the normal
range for our laboratory .
The values of blood gases before and 5 minutes after
IVIG infusion for different gammaglobulin concen-
trations and using different IgG infusion rates did not
show any significant difference. However, there were
significant changes in pCO
2
, HCO
3
, CO
2
 and base excess
(BE) without changes in pH, pO
2
 and O
2
 saturation 30
minutes after the end of the infusion at a flow rate of 16
mg/kg/min (Table 3).
There was a small, but significant, hemodilution
effect 5 min after infusion rates of both 4-8 and 16 mg/kg/
min of the 12% IVIG solution as shown by a decrease in
red-cell count, hematocrit and hemoglobin levels (Table
4). There was no difference in the hemodilution effect
between the 2 infusion rates. The percentage post-IVIG
Table 3
Venous blood gases before and after (5 and 30 minutes) 12% IVIG at infusion rate 16 mg/kg/min (N=4)
Before* 5 minutes* 30 minutes* P value
pH 7.36 (0.04) 7.35 (0.18) 7.36 (0.20) NS
pCO2 35.7 (5.28) 33.5 (1.85) 22.2 (4.63) 0.01
pO2 65.7 (16.92) 82.7 (8.31) 85.4 (13.06) NS
HCO3 20.12 (1.35) 18.77 (1.14) 12.6 (2.18) 0.003
CO2t 21.22 (1.54) 19.85 (1.17) 13.32 (2.34) 0.004
BE -4.25 (0.55) -5.6 (1.16) -11.55 (2.02) 0.001
SatO2 89.6 (6.92) 95.22 (1.28) 95.9 (3.03) NS
* Mean (SD)
Table 2
Mean plasma osmolarity (mOsm/l) of children with primary antibody deficiency before and after different
schedules of IVIG infusion
IVIG Concentration (%) 6 9 12 12 12 12
Infusion Rate (mg/kg/min) 4 4 4 8 12 16
Osmolarity (mOsm/l)
Before 281 277 285 282 284 283
After 289 286 302 296 302 282
% increase 2.8 3.2 5.9 4.9 6.3 -3.5
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infusion decrease was higher in white cells than in red
cells and the effect increased with increasing IgG infusion
rates (Table 4). The range of the decreases was 32 to 82%
at a flow rate of 4-8 mg/kg/min and 44 to 90% at a flow
rate of 16 mg/kg/min. Monocytes had the highest
percentage decrease in comparison to other white cells at
flow rates of both 4-8 and 16 mg/kg/min. The percentage
neutrophil decrease was lower at a flow rate of 4-8 than at
16 mg/kg/min (32% and 60% decrease, respectively).
Platelet numbers were also decreased after infusion, but
to a lesser degree than the white cells. The percentage
decrease was 21.5% at infusion rates of 4-8 mg/kg/min
and 31.2% at 16 mg/kg/min (Table 4).
DISCUSSION
Side effects such as chills, fever, flushing, headache,
nausea, increased temperature, vomiting and malaise are
considered mild adverse reactions of IVIG infusion. They
are often associated with an increased IgG infusion rate
and usually improve rapidly when the infusion rate is
lowered.9 These reactions have been attributed to antigen-
antibody reactions or to possible contaminants or even
stabilizers that may have been used during the
manufacturing process.5 The clinical side effects we
observed in 2 of our patients were mild and responsive to
infusion-rate reduction (IVIG 12% - 8 and 16 mg/kg/min).
In a third patient, we observed a persistent headache,
which remitted spontaneously after 12 hours (IVIG 12%
- 16 mg/kg/min). Acute aseptic meningitis has been
reported as a cause of recurrent IVIG-associated
headaches.10 Analysis of cerebrospinal fluid has revealed
neutrophilic pleocytosis with normal or mildly raised
protein levels.5,9 Whether or not the transient headache
seen in our patient was a mild form of aseptic meningitis
could not be determined since the performance of a
lumbar puncture was not clinically justifiable. In
accordance with the study by Camp-Sorrell et al. which
showed a weak correlation between vital signs during
IVIG administration and adverse reactions,11 we did not
observe significant changes in vital signs in our patients
who developed side effects.
The osmolarity of IVIG solutions increases with
increasing IgG concentrations. In addition to IgG, the IVIG
preparations utilized in this study contains 5-10% sucrose;
the diluent is sodium chloride. We observed a trend to
higher plasma osmolarity in all patients regardless of
clinical side effects, even at flow rates of 4 mg/kg/min.
The percentage of increase in osmolarity was higher with
the 12% IVIG preparations, independent of the flow rates.
No increase in osmolarity was observed with infusion rates
of 16 mg/kg/min, which may be due to the short infusion
time. We do not know whether, after longer periods of
time, e.g. 30 minutes after the end of infusion, we would
also have detected changes in plasma osmolarity at this
high flow rate. Some commercial IVIG preparations use
albumin and sugar as additives. Based on our results with
one IVIG preparation, we suggest that further studies
should evaluate changes in osmolarity caused by  other
IVIG preparations too.
Blood viscosity after IVIG infusion increases
proportionally to the IgG concentration in the preparation
used and may still be elevated 3 to 5 days after IVIG
infusion.12 The authors of this finding postulated that
changes in viscosity occurring after IVIG therapy could
impair blood flow and increase the risk of myocardial
infarction or stroke in patients at risk from cardiovascular
and thromboembolic events. Side effects of IVIG infusion,
such as acute renal failure13 and thromboembolic events14
may be associated with increasing plasma viscosity.
Therefore, increased plasma viscosity could represent an
Table 4
Blood cells count before and after Sandoglobulin® 12% infusion (5 minutes) at different flow rates
IgG infusion rate: 4-8 mg/kg/min IgG infusion rate: 16 mg/kg/min
(N=5) (N=4)
Before* After* %decrease P value Before* After* %decrease P value
Red cells (x106/mm3) 4.44 (0.05) 4.02 (0.29)          9.4% 0.02 4.35 (0.28) 3.97 (0.15) 8.7% NS
Hematocrit (%) 36 (1.58) 32 (1.64)       11.1% 0.009 35 (2.88) 32 (0.95) 8.5% 0.03
Hemoglobin (g/dl) 11.7 (0.39) 10.5 (0.93)      10.25% 0.05 11.3 (0.37) 10.2 (0.20)  9.7% 0.05
White cells (cells/mm3) 9400 (3276) 5960 (1903)       36.6% NS 8625 (4073) 3450 (1112)  60% 0.04
Neutrophils (cells/mm3) 6873 (2739) 4658 (966) 32.2% NS 8625 (2036) 3450 (556)  60% 0.04
Eosinophils (cells/mm3) 247 (221) 134 (95) 45.7% NS 242 (270) 103 (64) 57.4% NS
Lymphocytes (cells/mm3) 3480 (1530) 2058 (790)  40.8% 0.02 3396 (1743) 1895 (628) 44.2% NS
Monocytes (cells/mm3) 515 (247) 93 (68)  81.9% 0.02 658 (329) 62 (42)  90.5% 0.03
Platelets (x103) 331 (32) 260 (56)  21.5% 0.03 320 (118) 220 (60)  31.2% 0.04
* Mean (SD)
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additional risk for elderly patients and for HIV-infected
patients with hypergammaglobulinemia who receive large
amounts of IVIG. The relationship between changes in
osmolarity observed in our patients and the reported
changes in viscosity is unclear at this time. Further studies
of both changes need to be performed in parallel studies
in the same patients.
The pH of Sandoglobulin® is similar for all IgG
concentrations used and is comparable  to that of other
commercial IVIG preparations,15 but it is lower than that
of the human body pH. None of our patients presented
significant changes in blood pH, but 30 minutes after
infusion, they showed metabolic acidosis (base excess
consumption and fall in HCO
3
) compensated by
hyperventilation (fall in pCO
2
). This acidemia might be
induced by the acid solution or by the protein infused.
IVIG preparations should be used with caution in patients
with conditions which may impair their ability to
compensate for a large acid load.
The relatively small decrease in the number of red
cells after IVIG infusion, which was constant for different
flow rates, may be due to the dilution factor. The higher
percentage decrease in white cells, however, cannot be
attributed to hemodilution. Considering that the infused
volume was smaller when more concentrated IVIG
preparations were used, the sharp decrease in white-cell
numbers seems to be caused by the infused IgG. Transient
neutropenia following IVIG infusion has been described
in a 36 year-old woman with systemic lupus erythmatosus16
and in a newborn infant.17 The cause of the neutropenia
observed by these investigators and by us is unclear. It
may be related to the presence of anti-leukocyte antibodies
in IVIG or to the formation of immune complexes in the
circulation which could attach to the Fc receptors present
on circulating white cells.9 O’Donnell et al. observed an
increase in serum immune complex-like activity during
and after IVIG infusions.18 Another possibility is an altered
expression of cell-surface CR3, the receptor for C3bi, after
IVIG infusions with a consequent increase in adhesion of
neutrophils to blood vessels.18 An increase in leukocyte
adhesion molecule expression may also occur, resulting
in a higher adhesiveness to endothelial cells. We believe
that increased transendothelial migration across the blood-
brain barrier due to increased adhesion may present an
explanation for the pleocytosis found in acute aseptic
meningitis after IVIG infusion observed in some patients
after IVIG infusion.
IVIG has been used successfully for treatment of
idiopathic thrombocytopenic purpura. In these patients, a
rise in platelet count has been observed within 24 hours
with a peak increase about 10 days after therapy.19,20 We
observed a 20-30% decrease in platelets 5 minutes after
infusion, possibly due to platelet aggregation induced by
circulating immune complexes. None of our patients
manifested bleeding after IVIG infusion. Since the doses
of IgG utilized in the treatment of autoimmune diseases
are higher, our results suggest that the immediate effect of
IVIG on platelets need to be monitored in patients with
low platelet counts or other coagulation problems.
From the observations made thus far, we conclude that
high infusion rates with high-concentration IVIG
preparations induce significant immediate metabolic and
hematologic changes. In future studies, it will be important
to follow patients until the changes in laboratory parameters
reported here return to normal after IVIG infusion. While
high infusion rates may be tolerated clinically by the majority
of patients, changes observed may be implicated in the
adverse effects observed in some patients. We recommend
calculating infusion rates based on mg/kg/min and
monitoring patients carefully during and after IVIG
infusions. The advantages of using high infusion rates have
to be re-evaluated keeping in mind the potential side effects,
especially in high-risk patients such as with cardiac and
renal diseases and hypergammaglobulinemia (AIDS). We
also encourage reporting the side effects of the use of high
IgG infusion rates, since our experience suggests that
incidents attributable to the use of IVIG may be more
frequent than presently assumed.
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RESUMO
Objetivo: Nós pretendemos investigar se o aumento de velocidade de infusão de gamaglobulina intravenosa (IVIG), está
associada com alterações metabólicas e hematológicas em pacientes com deficiência de anticorpo. Casuística e Método:
Nós estudamos sete pacientes (2-16 anos) com deficiência primária de anticorpo que já estavam em tratamento com reposição
regular de IgG, na dose de 350-600 mg/kg a cada três semanas em preparados a 3%, por períodos de seis meses a quatro
anos. Inicialmente a concentração dos preparados de IVIG foi aumentando para  6, 9 e 12% em infusões consecutivas numa
velocidade constante 4 mg/kg/min. Subseqüentemente, na segunda fase do estudo, mantivemos a concentração a 12% e a
velocidade de infusão foi aumentando para 8, 12, e 16 mg/kg/min. Resultados: Clinicamente, todos os pacientes toleraram o
aumento da concentração de IVIG na velocidade constante de 4 mg/kg/min. Entretanto, 3 pacientes apresentaram efeitos
colaterais quando a velocidade de infusão aumentou para 8 e 16 mg/kg/min. Conclusão: Nós concluímos que alterações
metabólicas e hematológicas podem ocorrer quando se administra preparados de IVIG em altas concentração e velocidade
mesmo que os pacientes tolerem bem clinicamente. As vantagens de utilizar velocidades elevadas na infusão de IVIG devem
ser reavaliadas.
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